viewKazia Therapeutics Ltd

Kazia Therapeutics releases new safety data to assist in brain cancer treatments

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer James Garner speaks to Proactive Investors about new safety and tolerability data from the company's phase-IIa clinical trial of brain cancer treatment. 
Garner said the superior results from the ongoing study of GDC-0084 in newly diagnosed glioblastoma patients was an important milestone for the company.
He added the current, second stage of the two-part study (which began in September) will transition into observing more patients, with higher doses of the drug.

Quick facts: Kazia Therapeutics Ltd

Price: 0.8 AUD

Market: ASX
Market Cap: $92.12 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...


Kazia Therapeutics moves into operational phase of pivotal study for...

Kazia Therapeutics Ltd's (ASX:KZA) James Garner speaks to Proactive's Andrew Scott soon after announcing they've executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to begin participation in the GBM AGILE pivotal study in glioblastoma. The study is set to open...

3 days, 23 hours ago

2 min read